Search

Objective: To compare the frequency of new onset perioperative myocardial infarction in patients undergoing coronary artery bypass graft with and without long cross clamp time. Study Design: Randomized Control Trial. Setting: Department of Cardiac Surgery at the CH. Muhammad Akram Teaching and Research, Lahore. Period: 10th Feb 2023 to 10th June 2023. Methods: Patients were admitted through out-patient department one week prior to the operation and randomized to Group L (longer aortic cross-clamp time) and Group S (shorter time). Preoperative electrocardiogram was recorded for every patient. After surgery patients were shifted to intensive care unit. Development of perioperative myocardial infarction was the major outcome variable. Results: In our study, frequency of perioperative myocardial infarction in both groups was 7% in Group-L and 3% in Group-S with a p value was 0.19. Conclusion: In summary, our study sheds light on the notable difference in the frequency of perioperative myocardial infarction among patients undergoing CABG, particularly in relation to cross clamp time. While our findings present valuable insights, the necessity for further validation through multicenter trials with a larger sample size is evident. [ABSTRACT FROM AUTHOR]

The safe and targeted delivery of pharmaceutical formulations has relied extensively on synthetic chemistry and other physicochemical approaches. The research paradigm is now especially changing towards green (or environmentally friendly) approaches, and several biopolymer‐based nanocarriers are marked as emerging nanomedicine tools. These have been developed to overcome problems with conventional drug carriers, which induce severe side effects, especially due to non‐specificity with detrimental effects on non‐targeted normal healthy cells. In addition, the phagocytosis of classic nanoparticles (NPs) and their degradation associated with the formation of oxygen radicals by the immune system are significant barriers for drug delivery. In this regard, protein nanocarriers appear as a promising approach to escape unwanted immune reactions. Moreover, these protein‐based NPs are generally non‐toxic, biodegradable, and even cost‐effective. As a less appreciated advantage, the surface properties of proteins are easily modified. There are, however, several challenges and limiting choices to make when choosing the type of modification to enable effective drug delivery. Here, we shed light on the role of protein nanocarriers for enhancing the bioavailability of different anti‐inflammatory drugs, including better macrophage targeting and overcoming biological barriers. This insight helps one to understand their broad utility in the treatment of inflammatory diseases and bridges the gap between naturaltherapeutic products and nanotechnology‐based delivery approaches, creating perhaps an optimal blend to meet some of our most persistent healthcare problems. [ABSTRACT FROM AUTHOR]